IPO fundraising hits a two-year low as big deals dominate

IPO fundraising has started to resemble a sorting mechanism in 2026 rather than a clean reopening. The first lesson from the early-year slowdown is not that buyers have disappeared, but that equity capital markets desks now have to ration attention across a much narrower set of names. In that environment, a blockbuster like SpaceX can still attract extraordinary demand while the wider queue waits for calmer screens and sharper pricing.

India offers one of the clearest readouts on that shift. The Economic Times reported that companies raised Rs 56,322 crore through IPOs in the first five months of 2026, down from Rs 82,678 crore a year earlier and Rs 72,841 crore in the same stretch of 2024, even though 207 companies are already approved or awaiting clearance to raise about Rs 3 lakh crore. Supply is there. What is missing is the broad, indiscriminate risk appetite that let almost any credible issuer test the market in late 2025.

Ravi Singh, chief research officer at Master Capital Services, told The Economic Times that the tape, not the pipeline, has done most of the damage.

“Weak momentum in the first five months was largely a result of volatile secondary markets, stretched valuations and cautious institutional participation because of global macro uncertainties.”
— Ravi Singh, Master Capital Services, via The Economic Times

But Lukas Muehlbauer at IPOX reads the same backlog as a warning against false signals. A spectacular debut by SpaceX, or later by OpenAI and Anthropic, would show that capital still exists for scarce growth stories. It would not prove that the ordinary issuer, the industrial roll-up, the consumer brand with middling margins, or the regional bank spin-off can suddenly clear the market on similar terms.

The market is narrowing, not closing

That is why Samuel Kerr, global head of equity capital markets at Mergermarket, matters more here than the cheerleaders of a simple IPO comeback. In a CNBC interview, Kerr argued that a single mega-deal can absorb far more than headlines imply, because funds that feel they must participate often make room by trimming something else. The market can be open and still feel thin.

The numbers from India show the same logic at work. Subscription levels averaged just 2 times in February and March, versus 38 times in the second half of calendar 2025, according to The Economic Times. That kind of collapse does not describe a market with no interest at all. It describes one in which investors have moved from chasing volume to interrogating valuation, secondary liquidity and geopolitical exposure deal by deal.

Reuters has already documented that shift outside India as well. In February, Reuters reported that companies were trimming or delaying flotations as market volatility tested valuations, and its later India File on Jio argued that Reliance’s rethink on timing may amount to a reset for a drowsy IPO market rather than a one-off hesitation. The common thread is discipline: if a company is not large, unusual or obviously scarce, buyers are no longer paying up simply because the calendar says the window is open.

Europe offers similar texture. CNBC reported that SpaceX’s expected June debut arrives while Europe’s IPO market is still struggling to regain momentum, a reminder that the backlog problem is not confined to one geography. Even where issuance calendars are technically open, the practical test is whether a second-tier name can hold the range once the first wave of orders is in.

That distinction matters for the second half. Brand-name offerings can still set the tone for headlines, but they do not necessarily repair the financing conditions for everyone behind them. They may simply confirm that the public market wants scale and narrative at the same time.

Why SpaceX is not the bellwether

Muehlbauer’s central point is that SpaceX sits outside normal market geometry. In Reuters’ analysis, he said the company is too large and too unusually valued to serve as a standard test of IPO health. That is hard to dismiss when the Financial Times has framed SpaceX, OpenAI and Anthropic as offerings that could push combined fundraising beyond the record set in 2021.

“SpaceX is so large and extraordinarily valued that it doesn’t lend itself as a normal test case for the IPO market.”
— Lukas Muehlbauer, IPOX, via Reuters

The builder-optimist case is easy to understand. Venture backers and growth investors can argue that giant AI and space listings are exactly what public markets have been missing: scarce assets, strong narratives and capital needs big enough to justify headline valuations. If those deals print well, they will validate the idea that cash on the sidelines still exists. Yet that answer only goes halfway. It says buyers can be mobilized for exceptional assets, not that the middle of the market is healthy again.

That is why the venture case and the ECM case can diverge. Backers look at whether flagship tech groups can secure public-market prices close to late-stage private marks. Syndicate desks care about what happens to everyone priced in the shadow of those floats. A triumphant SpaceX launch could settle the first question and worsen the second.

Kerr made the crowding-out risk plainer in his CNBC comments.

“It has the potential to really suck all the oxygen out the room for anybody else.”
— Samuel Kerr, Mergermarket, via CNBC

That line answers one of the market’s most practical questions: do mega-deals crowd out smaller issuers, or merely reveal latent demand? At least in the short run, they can do both. They reveal that appetite exists, then redirect it toward the biggest names, leaving everyone else to price more conservatively or wait.

The flow problem matters more than the headline count

The most underappreciated perspective may be the user-affected one, not the issuer’s. As The Conversation noted in its discussion of future AI listings, large companies entering public benchmarks can create automatic exposure for index-tracking funds. CNBC’s report on retail access to the SpaceX IPO suggests brokerages are widening the funnel even further. That broadens the buyer base, but it does not create infinite balance-sheet room. It changes who absorbs supply.

Passive demand and retail access can smooth an opening print, but they do not solve aftermarket digestion. Index funds buy because rules tell them to, while retail orders often chase headlines. Neither pool is a perfect substitute for the long-only institutional demand that smaller issuers still need to support ranges, allocations and post-listing stability.

The Financial Times pushed that point further in a separate analysis of IPO mania as a possible market-top signal. Its argument was not that every major float marks the end of a bull run. It was that large offerings tend to increase stock supply near market highs, and that the absorption of that supply can leave the broader market weaker afterward. In other words, a reopening in the primary market can coexist with a thinner secondary market, especially if funds must rotate out of existing holdings to make room.

That is the deeper reason the two-year low in fundraising matters. It is not just a statistic about one sluggish stretch of issuance. It is evidence that 2026 is becoming a more selective market structure story, one in which the winners may be obvious long before the calendar clears. Bankers, sponsors and investors should watch not only whether SpaceX or OpenAI can get done, but whether the deal after them can price without apology. If it cannot, the IPO window is not really back. It is merely concentrated in the hands of the giants.